Author

Qiu-Lan Zhang

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

In vivo gene editing with YOLT-201 for transthyretin amyloid cardiomyopathy – an open-label, first-in-human clinical trial

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and life-threatening disease driven by continuous hepatic production of misfolded transthyretin. Existing therapies slow progression but require chronic administration. YOLT-201 is an in vivo CRISPR-Cas9 gene-editing therapy delivered by lipid nanopa...

X. Guo, H. Yan, J. Liao et al. · European Heart Journal · 0 citations

Review Open access Oct 2026

Ultrasound-responsive nanoplatforms for cancer immunotherapy: engineering spatiotemporal immune activation in the tumor microenvironment

Immune checkpoint blockade has reshaped cancer therapy, but durable responses remain limited by insufficient antigen release, poor T-cell infiltration, immunosuppressive tumor microenvironments, and systemic immune-related toxicity. Ultrasound-responsive nanoplatforms provide a spatiotemporally controllable strategy to...

Qiu-Lan Zhang, T. Wei, Zhen-Hao Lan et al. · Frontiers in Immunology · 0 citations